These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21124201)

  • 1. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.
    Smurzynski M; Wu K; Letendre S; Robertson K; Bosch RJ; Clifford DB; Evans S; Collier AC; Taylor M; Ellis R
    AIDS; 2011 Jan; 25(3):357-65. PubMed ID: 21124201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.
    Marra CM; Zhao Y; Clifford DB; Letendre S; Evans S; Henry K; Ellis RJ; Rodriguez B; Coombs RW; Schifitto G; McArthur JC; Robertson K;
    AIDS; 2009 Jul; 23(11):1359-66. PubMed ID: 19424052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
    Letendre S; Marquie-Beck J; Capparelli E; Best B; Clifford D; Collier AC; Gelman BB; McArthur JC; McCutchan JA; Morgello S; Simpson D; Grant I; Ellis RJ;
    Arch Neurol; 2008 Jan; 65(1):65-70. PubMed ID: 18195140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
    Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S
    Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients.
    Casado JL; Marín A; Moreno A; Iglesias V; Perez-Elías MJ; Moreno S; Corral I
    J Neurovirol; 2014 Feb; 20(1):54-61. PubMed ID: 24420449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
    Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
    J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.
    Tozzi V; Balestra P; Salvatori MF; Vlassi C; Liuzzi G; Giancola ML; Giulianelli M; Narciso P; Antinori A
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):56-63. PubMed ID: 19731418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?
    Marra CM
    Antivir Ther; 2015; 20(4):365-7. PubMed ID: 25781980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV Antiretroviral Medication Neuropenetrance and Neurocognitive Outcomes in HIV+ Adults: A Review of the Literature Examining the Central Nervous System Penetration Effectiveness Score.
    Arentoft A; Troxell K; Alvarez K; Aghvinian M; Rivera Mindt M; Cherner M; Van Dyk K; Razani J; Roxas M; Gavilanes M
    Viruses; 2022 May; 14(6):. PubMed ID: 35746623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?
    McManus H; Li PC; Nolan D; Bloch M; Kiertiburanakul S; Choi JY; Mulhall B; Petoumenos K; Zhou J; Law M; Brew BJ; Wright E
    HIV Med; 2011 Nov; 12(10):610-9. PubMed ID: 21819527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy.
    Marra CM; Maxwell CL; Collier AC; Robertson KR; Imrie A
    BMC Infect Dis; 2007 May; 7():37. PubMed ID: 17475004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.
    Mukerji SS; Misra V; Lorenz DR; Uno H; Morgello S; Franklin D; Ellis RJ; Letendre S; Gabuzda D
    Clin Infect Dis; 2018 Sep; 67(8):1182-1190. PubMed ID: 29617912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.
    Cross HM; Combrinck MI; Joska JA
    S Afr Med J; 2013 Sep; 103(10):758-62. PubMed ID: 24079630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score.
    Kahouadji Y; Dumurgier J; Sellier P; Lapalus P; Delcey V; Bergmann J; Hugon J; Paquet C
    HIV Med; 2013 May; 14(5):311-5. PubMed ID: 23035982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
    Livelli A; Vaida F; Ellis RJ; Ma Q; Ferrara M; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Grant I; Letendre SL;
    Lancet HIV; 2019 Jul; 6(7):e456-e462. PubMed ID: 31208949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.
    Caniglia EC; Cain LE; Justice A; Tate J; Logan R; Sabin C; Winston A; van Sighem A; Miro JM; Podzamczer D; Olson A; Arribas JR; Moreno S; Meyer L; del Romero J; Dabis F; Bucher HC; Wandeler G; Vourli G; Skoutelis A; Lanoy E; Gasnault J; Costagliola D; Hernán MA;
    Neurology; 2014 Jul; 83(2):134-41. PubMed ID: 24907236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
    Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
    AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
    Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
    J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial.
    Kambugu A; Thompson J; Hakim J; Tumukunde D; van Oosterhout JJ; Mwebaze R; Hoppe A; Abach J; Kwobah C; Arenas-Pinto A; Walker SA; Paton NI;
    J Acquir Immune Defic Syndr; 2016 Apr; 71(5):506-13. PubMed ID: 26579985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
    Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
    J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.